Form 4: BridgeBio Pharma CFO Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
BridgeBio Pharma's CFO, Brian C. Stephenson, sold 4,156 shares of common stock at an average price of $22.4102, as part of a pre-arranged 10b5-1 trading plan.
Summary
- Brian C. Stephenson, the Secretary, Treasurer, and CFO of BridgeBio Pharma, Inc., sold 4,156 shares of the company's common stock on November 19, 2024.
- The sale was executed at a weighted average price of $22.4102 per share.
- The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 22, 2024.
- Following the transaction, Stephenson directly owns 93,758 shares of BridgeBio Pharma common stock.
Sentiment
Score: 5
Explanation: The document reflects a routine insider stock sale under a pre-arranged plan, which is neither positive nor negative for the company's outlook. It's a neutral event.
Risks
- Sales by company insiders can sometimes be perceived negatively by the market, potentially impacting the stock price.
Industry Context
Insider trading activity is a common occurrence in publicly traded companies, and sales under 10b5-1 plans are a routine way for executives to manage their personal finances while avoiding accusations of trading on non-public information. This is a standard practice and does not necessarily indicate a change in the company's outlook.
Comparison to Industry Standards
- Sales by executives under 10b5-1 plans are common across the pharmaceutical and biotech industries, with companies like Amgen, Gilead, and Regeneron having similar filings.
- The volume of shares sold by Stephenson is relatively small compared to the total outstanding shares of BridgeBio Pharma, and is not unusual for a CFO's planned sales.
- The price range of $21.95 to $22.78 is within the typical trading range for BBIO stock, suggesting no unusual market activity related to this sale.
Stakeholder Impact
- The sale may have a minor impact on shareholder sentiment, but is unlikely to significantly affect the company's operations or financial health.
Key Dates
| Date | Description |
|---|---|
| 03/22/2024 | Date the Rule 10b5-1 sales plan was adopted by Brian C. Stephenson. |
| 11/19/2024 | Date of the stock sale transaction. |
| 11/20/2024 | Date the Form 4 was signed. |
Keywords
BridgeBio Pharma, BBIO, insider trading, Form 4, Rule 10b5-1, stock sale, Brian C. Stephenson, CFO, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.